Taylor Taylor J J Pavlick Pavlick D D Yoshimi Yoshimi A A Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies J Clin Invest J Clin Invest 2018 2018 128 128 3819 3819 3825 3825 supplied-pmid 29920189? This evidence concerns the gene NTRK1 and hematologic disorder.